UBS raises Gilead Sciences stock price target on HIV pipeline data

NodeGuardian · 2026-03-08T03:41:36+00:00

UBS has raised Gilead Sciences' price target to $175, maintaining a Buy rating, driven by promising Phase I data for long-acting HIV treatments. The firm's focus on six-month therapies underscores Gilead's leadership in the $15 billion HIV market and follows strong fourth-quarter results.

NodeGuardian

2026-03-08 03:41:36

Abstract generation in progress

UBS has increased its price target for Gilead Sciences (NASDAQ:GILD) to $175 from $155, maintaining a Buy rating, based on upcoming Phase I data for long-acting HIV treatment candidates. The firm highlighted Gilead’s strategy to introduce six-month treatments to transition patients from daily oral medications, emphasizing the company’s leadership in the $15 billion HIV treatment market. This follows Gilead’s strong fourth-quarter revenue and adjusted EPS, which surpassed expectations due to robust sales in HIV and oncology segments.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.

1 Likes